PD-L1 expression in gastric adenocarcinoma
Main Article Content
Abstract
Gastric cancer is the third most common cancer and the third leading cause of cancer-related death in Vietnam. Anti PD-1 and anti PD-L1 monoclonal antibodies, called immune checkpoint inhibitors, have shown promise in patients with gastric cancer. Our study is to assess the expression of PD-L1 on gastric adenocarcinoma and the relationship with clinicopathological features. Tissue samples were collected from patients who underwent surgical resection for gastric cancer without preoperative chemotherapy at the Hanoi Oncology Hospital and Bach Mai Hospital, between October 1, 2020 and August 31, 2021. The expression of PD-L1 was detected via immunohistochemistry in 96 gastric adenocarcinoma samples, using Rabbit monoclonal antibody (73-10, Leica). Positive staining was defined as CPS≥1. The result is that about 38.5% of gastric adenocarcinoma tissues showed positive PD-L1 immunolabeling. There was no correlation between PD-L1 and age, sex, tumor location, tumor size, tumor differentiation of patients, vascular invastion and perineural invasion (p>0.05). However, PD-L1 was significantly correlated to lymph node metastasis and the deepth of tumor invastion (p<0.05).
Article Details
Keywords
gastric adenocarcinoma, PD-L1, immune checkpoint inhibitors.
References
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi:10.1146/annurev.immunol.26.021607.090331
3. Dong H, Chen L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med. 2003;81(5):281-287. doi:10.1007/s00109-003-0430-2
4. Shitara K, Van Cutsem E, Bang Y-J, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncology. 2020;6(10):1571-1580. doi:10.1001/jamaoncol.2020.3370
5. Research C for DE and. FDA approves new dosing regimen for pembrolizumab. FDA. Published online April 29, 2020. Accessed October 18, 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-new-dosing-regimen-pembrolizumab
6. Gu L, Chen M, Guo D, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS One. 2017;12(8):e0182692. doi:10.1371/journal.pone.0182692
7. Heo YJ, Kim B, Kim H, Kim S, Jang MS, Kim K-M. PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study. Pathol Res Pract. 2021;218:153338. doi:10.1016/j.prp.2020.153338
8. Doi T, Iwasa S, Muro K, et al. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer. 2019;22(4):817-827. doi:10.1007/s10120-018-0903-1
9. Moehler M, Dvorkin M, Boku N, et al. Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. JCO. 2021;39(9):966-977. doi:10.1200/JCO.20.00892
10. Park Y, Koh J, Na HY, et al. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res Treat. 2020;52(3):661-670. doi:10.4143/crt.2019.718
11. Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2015;20(2):273-281. doi:10.1007/s10147-014-0701-7
12. Wu Y, Cao D, Qu L, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8(38):64066-64082. doi:10.18632/oncotarget.19318
13. Hou J, Yu Z, Xiang R, et al. Correlation between infiltration of FOXP3+ regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Experimental and Molecular Pathology. 2014;96(3):284-291. doi:10.1016/j.yexmp.2014.03.005
14. Kim DH, Bae GE, Suh KS, et al. Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma. In Vivo. 2020;34(6):3171-3180. doi:10.21873/invivo.12152